US › Healthcare

Actinium Pharmaceuticals Inc (ATNM)

US · Healthcare · Biotechnology

$0.81-0.18%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-5.5M

Profit YoY

+65.4%

EPS

$-0.18

EPS estimate

$-0.22

EPS came in at -0.18 against a street estimate of -0.22 — a beat of 18.2%.

Key statistics

Market cap

$25.5M

Forward P/E

6.8

P/B

11.40

Book value

$0.07

EPS (TTM)

$-0.76

52-week high

$1.81

52-week low

$0.81

50-day MA

$1.00

200-day MA

$1.22

Beta

0.02

Analyst view

Analysts rate Actinium Pharmaceuticals Inc a buy (4 buy, 1 hold, 0 sell out of 5) with an average price target of $5.00.

Shareholding

Insiders

2.35%

Institutions

20.61%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Actinium Pharmaceuticals Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.